Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

Perioral Dermatitis Clinical Trial

Official title:
A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

Status Completed

Clinical Trial Summary

A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

Clinical Trial Description

This pilot study's intended purpose is to evaluate the efficacy, safety, and tolerability of sarecycline for periorificial dermatitis. Sarecycline, a third-generation tetracycline, is currently only indicated to treat acne vulgaris. However, the investigator has used sarecycline to treat periorificial dermatitis and would like to capture and report on this efficacy in a pilot study. The investigator hypothesize's that not only will the subjects respond well to sarecycline treatment, but that it will be well-tolerated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06461299
Study type	Interventional
Source	The Dermatology Institute of Boston
Contact
Status	Completed
Phase	Phase 4
Start date	July 17, 2023
Completion date	March 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00232115` - Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis	Phase 3
Completed	`NCT00403949` - A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis	Phase 2
Withdrawn	`NCT03779295` - Laser Therapy for Perioral Dermatitis	N/A